Berobenatide vs Ecnoglutide (VRB-101)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
Berobenatide
Developed by Pfizer
NCT06712836 · Phase 2 · completed
The study randomized 239 participants to MET097 or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary endpoint was the clinical outcome of body-weight change at Week 28. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2027 · NCT07508241 (registry estimate)
Reported efficacy
Percent change from baseline in body weight at Week 28 (Baseline (Week 0) through Week 28 (Day 197)): Percent change in body weight at week 28 (Part A): berobenatide 0.4, 0.6, 0.9 and 1.2 mg weekly -6.41%, -8.36%, -11.29% and -12.45% vs placebo +1.67%; placebo-adjusted -8.09% to -14.13%, all p<0.0001 (CT.gov posted results). (met)
Result source: NCT06712836
Ecnoglutide (VRB-101)
Developed by Verdiva Bio under a licence from Sciwind Biosciences
NCT07281937 · Phase 2 · completed
The trial randomly assigns participants to VRB-101 or a matching placebo and keeps participants, care providers and assessors all blinded, using percent body weight change, a standard measure for obesity drugs, as its main result. Results have not been posted yet, so whether the weight-loss difference was statistically meaningful is not yet known. (Independently confirmed by a second model, in-session-confirm:claude-opus-20260822.)
Next expected readout: January 2027 · NCT07243171 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Berobenatide | Ecnoglutide (VRB-101) |
|---|---|---|
| Body weight, % change | —Trial running · NCT07311850 | —Not reported |
| Weight loss of 5% or more | —Trial running · NCT07311850 | —Not reported |
| Weight loss of 10% or more | —Trial running · NCT07311850 | —Not reported |
| Waist circumference, change (cm) | —Trial running · NCT07311850 | —Not reported |
Body weight, % change
- Berobenatide
- —Trial running · NCT07311850
- Ecnoglutide (VRB-101)
- —Not reported
Weight loss of 5% or more
- Berobenatide
- —Trial running · NCT07311850
- Ecnoglutide (VRB-101)
- —Not reported
Weight loss of 10% or more
- Berobenatide
- —Trial running · NCT07311850
- Ecnoglutide (VRB-101)
- —Not reported
Waist circumference, change (cm)
- Berobenatide
- —Trial running · NCT07311850
- Ecnoglutide (VRB-101)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ecnoglutide (VRB-101): no structured comparison results are available for Obesity.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Berobenatide's landscape · Ecnoglutide (VRB-101)'s landscape